

Synthesis of Fervenuin 4-Oxide and Its Conversion to the Antibiotics Fervenuin and 2-Methylfervenuinone¹

Misuzu Ichiba, Sadao Nishigaki, and Keitaro Senga*

Pharmaceutical Institute, School of Medicine, Keio University,
35, Shinanomachi, Shinjuku-ku, Tokyo 160, Japan


Received July 15, 1977

Normally inaccessible fervenuin 4-oxide (5) was synthesized in a single step by the reaction of 1,3-dimethyl-6-hydrazino-5-nitrosouracil (4) with one-carbon reagents (dimethylformamide-phosphorus oxychloride, dimethylformamide-dimethyl sulfate, formic acid, and triethyl orthoformate). Compound 5 was found to be a versatile intermediate for the synthesis of antibiotics fervenuin (1) and 2-methylfervenuinone (MSD-92) (2). Namely, the antibiotic 1 could be synthesized in the highest yield when 5 was treated with sodium hydrosulfite in water. The antibiotic 2 was synthesized most conveniently by the following three steps: treatment of 5 with dimethylformamide-phosphorus oxychloride afforded 3-chloro-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione (14), followed by acid hydrolysis to fervenuinone (15), and subsequent alkylation with methyl iodide in dimethylformamide containing potassium carbonate. Some derivatives related to 1 or 5 were also prepared from 4 or 5.

In recent years considerable chemical and medicinal interest has been focused on the pyrimido[5,4-*e*]-*as*-triazine (7-azapteridine) ring system primarily because of the attractive biological activities displayed by the antibiotics fervenuin (1), 2-methylfervenuinone (MSD-92) (2), and toxoflavin (3).² In connection with our recent studies on the synthesis of purines³ and pteridines⁴ from 6-amino-1,3-dimethyl-5-nitrosouracil, we have now examined the reaction of readily available 1,3-dimethyl-6-hydrazino-5-nitrosouracil (4)⁵ with various one-carbon reagents (dimethylformamide-


by the nitrosative cyclization of 6-alkylidene(or benzyldene)hydrazino-1,3-dimethyluracils in the presence of diethyl azodicarboxylate. However, the preparation of 5 itself has not been described. We now wish to report four new one-step syntheses of 5 and its successful conversion to the antibiotics 1 and 2 as well as to some derivatives related to 1.

Fervenuin 4-Oxide. Treatment of 4 with a mixture of dimethylformamide and phosphorus oxychloride (Vilsmeier reagent) at 0 °C followed by stirring at room temperature for 30 min gave 5 in 72% yield (method A). The structure of 5 was assigned by the satisfactory elemental analysis and spectral data. The mass spectrum showed a strong parent ion at *m/e* 209 and a remarkable *M*⁺ - 16 ion due to the presence of *N*-oxide. The NMR spectrum revealed the presence of two *N*-methyl groups (δ 3.45 and 3.80) and a single aromatic proton (δ 10.30). The structure of 5 was finally corroborated by its successful reduction to the antibiotic 1 (vide infra). The formation of 5 presumably proceeds through the *N,N*-dimethylaminomethylenehydrazino intermediate 6, followed by cyclization, and subsequent aromatization by loss of dimethylamine.⁹ There seem to be no previous instances in which the Vilsmeier reagent has been used for the synthesis of heterocyclic *N*-oxides. Method A was found to be greatly dependent on the reaction temperature. When this reaction was attempted without cooling, the product obtained was not 5 but *v*-triazolo[4,5-*d*]pyrimidine derivatives (9),¹⁰ which arise from the intramolecular dehydrative cyclization of 4. In analogy with method A, treatment of 4 with dimethylformamide-dimethyl sulfate complex⁶ (a modified Vilsmeier reagent) at room temperature for 2 h afforded a 43% yield of 5, probably via the same intermediate with that of method A (method B). Refluxing 4 with formic acid for 30 min also provided a 54% yield of 5, presumably formed via the dehydrative cyclization of a formylhydrazino intermediate 7 (method C). Furthermore, heating 4 with triethyl orthoformate at 90 °C for 30 min caused the separation of 5 in 71% yield (method D). This method appears to have greater scope than those of methods A, B, and C, and constitutes a general synthetic route to fervenuin 4-oxide derivatives. For example, the reaction of 4 with triethyl orthoacetate or triethyl orthopropionate under the conditions described above furnished the corresponding 3-alkylfervenuin 4-oxides, 10⁷ and 11, in high yields. The condensation of 4 with ortho esters may be involved with the intermediacy of α -ethoxyalkylidenehydrazino derivative 8, which undergoes cyclization by the elimination of ethanol. In general, the proposed intermediates, 6, 7, and 8, described in the above reactions can exist in either nitroso or oxime forms; however, these cyclizations may be facilitated by the nucleophilicity of the latter. The partici-



phosphorus oxychloride, dimethylformamide-dimethyl sulfate,⁶ formic acid, and triethyl orthoformate) and have found that the respective product is surprisingly fervenuin 4-oxide (5), which is a versatile intermediate for the synthesis of pyrimido[5,4-*e*]-*as*-triazine derivatives including the antibiotics 1 and 2.

The 4-oxide 5 seems to be less accessible by the conventional peroxy acid oxidation since the π -electron distribution of 1 calculated by the Hückel LCAO-MO method indicates that the most reactive site for the oxidation is position 1.⁷ In fact, the oxidation of 1 with trifluoroperacetic acid has been shown to give fervenuin 1-oxide.⁸ Recently, Yoneda et al.⁷ reported the synthesis of 3-substituted fervenuin 4-oxides



pation of oxime groups as nucleophiles has been well documented¹¹ (Scheme I).



Fervenuin and 2-Methylfervenuinone. The total syntheses of antibiotics fervenuin (1)^{5,8,12-16} and 2-methylfervenuinone (MSD-92) (2)¹⁵ have been accomplished. We have now examined a new synthetic approach to these antibiotics starting with fervenuin 4-oxide (5) obtained above.


Antibiotic 1 could be obtained in an excellent yield by the reduction of 5 with aqueous sodium hydrosulfite at room temperature. Compound 1 thus obtained was identical in all respects with the authentic sample prepared by the reported procedure.⁵ Analogously, compounds 10 and 11 were converted to the corresponding 3-alkylfervenuins, 12 and 13. The deoxygenation of *N*-oxide function of 5 to 1 was also achieved by the prolonged heating with dimethylformamide in less satisfactory yield (Scheme II).

Antibiotic 2 was prepared most conveniently by three steps starting with 5 as described below. Treatment of 5 with a mixture of dimethylformamide and phosphorus oxychloride at 50 °C afforded the chloro derivative 14¹⁵ in 84% yield. Heating 14 with either formic acid¹⁷ at reflux or 2 N hydrochloric acid at 90 °C gave fervenuinone (15),¹⁵ the precursor of 2, in 89 and 51% yield, respectively. Compound 15 could also be obtained from 14 by the indirect route. Thus the nucleophilic displacement of chloride from 14 with sodium ben-

zyloxyde gave the benzyloxy derivative 16, and the subsequent removal of the benzyl group by catalytic reduction with palladium charcoal provided 15 in 50% yield. The final alkylation was accomplished in almost quantitative yield by the reaction of 15 with methyl iodide in dimethylformamide containing potassium carbonate. The spectral data (IR, NMR, MS, and UV) of the synthetic compound and those of the authentic sample described in the literature¹⁸ proved to be identical (Scheme III).

In connection with 15, we also attempted the direct synthesis of 15 from 5 since various heterocyclic *N*-oxides have been known to react with nucleophiles to give α -hydroxy compounds.¹⁹ However, these attempts were found to be unsuccessful. Thus, treatment of 5 with tosyl chloride in





chloroform caused the ring cleavage of the *as*-triazine nucleus to give the starting material (4), which was alternatively obtained by the action of methanolic hydrochloric acid on 5. Refluxing 5 with acetic anhydride gave only 1. Treatment of 5 with a mixture of acetic anhydride and acetic acid furnished 5-acetylamino-1,3-dimethylbarbituric acid (17), which was identical with the sample prepared by the acetylation of 5-amino-1,3-dimethylbarbituric acid (18)²⁰ with a mixture of acetic anhydride and acetic acid.²¹ In contrast to the acids, treatment of 5 with 0.5% sodium hydroxide resulted in the deoxygenation of the *N*-oxide group and ring contraction of the pyrimidine moiety to give a new class of azapurine, imidazo[4,5-*e*]-*as*-triazine derivative (19), in 40% yield.²² The structure of 19 was supported by the elemental analysis and spectral data. In particular the IR spectrum revealed a characteristic carbonyl band at 1750 cm⁻¹,²³ and the NMR spectrum showed the presence of two *N*-methyl groups (δ 3.31 and 3.40) and a single aromatic proton (δ 10.23). The mechanism of this ring contraction probably involves a benzylic acid type rearrangement which has been discussed in the conversion of a certain pyrimido[5,4-*g*]pteridine 5-oxide to an imidazo[4,5-*b*]pyrazine by the action of sodium hydroxide.²⁴ The photoirradiation of 5 in ethanol provided only 1 in 54% yield and no rearrangement of the *N*-oxide group was observed (Scheme IV).

Experimental Section

Melting points were taken on a Yanagimoto melting point apparatus and are uncorrected. IR spectra were recorded on a Japan Spectroscopic Co., Ltd. Model IR-E spectrophotometer from samples milled in Nujol. NMR spectra were determined at 60 MHz with a Varian T-60 spectrometer using tetramethylsilane as the internal standard. UV spectra were recorded on a Hitachi 124 spectrophotometer. Mass spectra were performed on a JMS D100 EI spectrometer by a direct inlet system at 75 eV.

6,8-Dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione 4-Oxide (Fervenuin 4-Oxide (5)). **Method A.** The suspension of 1,3-dimethyl-6-hydrazino-5-nitrosouracil (4)⁵ (0.199 g, 0.001 mol) in dry DMF (3 mL) was stirred at 0 °C while the Vilsmeier reagent prepared from dry DMF (0.29 g, 0.004 mol) and POCl₃ (0.153 g, 0.001 mol) was added dropwise. When the addition was complete the reaction mixture was allowed to warm to room temperature and stirred for 30 min. The resulting solution was diluted with EtOH (2 mL) and evaporated in vacuo. The residue was poured onto ice-water and the precipitated solid was filtered. Recrystallization from EtOH gave 5 (0.15 g, 72%); mp 179–180 °C; IR 1715, 1660 cm⁻¹ (CO); NMR (CDCl₃) δ 3.45 (s, 3 H, NCH₃), 3.80 (s, 3 H, NCH₃), 10.30 (s, 1 H, C³H); UV λ_{\max} (EtOH) 240 nm (log ϵ 4.10), 304 (3.21), 323 sh (2.78); MS *m/e* 209 (M⁺), 193 (M⁺ - 16).

Anal. Calcd for C₇H₇N₅O₃: C, 40.19; H, 3.37; N, 33.48. Found: C, 39.92; H, 3.41; N, 33.76.

When this reaction was carried out without cooling, 4,6-dimethyl-*v*-triazolo[4,5-*d*]pyrimidine-5,7(4*H*,6*H*)-dione (9) (0.1 g, 55%), mp 259–260 °C (lit.¹⁰ mp 260 °C), identical (IR) with an authentic sample,¹⁰ was obtained after evaporation of the reaction mixture, followed by recrystallization of the residue from H₂O.

Method B. A mixture of 4 (0.199 g, 0.001 mol) and dimethylformamide-dimethyl sulfate complex⁶ (0.6 g, 0.003 mol) was stirred at

room temperature for 2 h. The resulting solution was diluted with EtOH (1 mL) and the precipitates were filtered. Recrystallization from EtOH afforded 5 (0.09 g, 43%), mp 179–180 °C, identical with a sample of 5 prepared by method A.

Method C. A mixture of 4 (0.199 g, 0.001 mol) and HCOOH (3 mL) was refluxed for 30 min and the reaction mixture was evaporated in vacuo. The residue was recrystallized from EtOH to give 5 (0.11 g, 54%), mp 179–180 °C, identical in all respects with the material prepared as described above.

Method D. A suspension of 4 (0.199 g, 0.001 mol) in triethyl orthoformate (3 mL) was heated at 90 °C for 30 min. After cooling the reaction mixture, the precipitated solid was filtered and recrystallized from EtOH to give 5 (0.148 g, 71%), mp 179–180 °C, identical with the material prepared by methods A, B, and C.

3-Alkyl-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione 4-Oxides (3-Alkylfervenuin 4-Oxides (10 and 11)). **General Procedure.** A mixture of 4 (0.199 g, 0.001 mol) and the respective ortho esters (2 mL) was heated for 30 min at 90 °C. The resulting solution was evaporated in vacuo and the residue was recrystallized from an appropriate solvent to give the corresponding fervenuin 4-oxides (10 and 11).

Compound 10: recrystallized from EtOH (0.17 g, 76%); mp 137–138 °C (lit.⁷ mp 138 °C); IR 1715, 1660 cm⁻¹ (CO); MS *m/e* 223 (M⁺), 207 (M⁺ - 16). Anal. Calcd for C₈H₉N₅O₃: C, 43.05; H, 4.06; N, 31.38. Found: C, 43.06; H, 4.06; N, 31.65.

Compound 11: recrystallized from EtOAc (0.2 g, 85%); mp 145.5–147 °C; IR 1725, 1670 cm⁻¹ (CO); MS *m/e* 237 (M⁺), 221 (M⁺ - 16). Anal. Calcd for C₉H₁₁N₅O₃: C, 45.57; H, 4.67; N, 29.53. Found: C, 45.22; H, 4.62; N, 29.27.

6,8-Dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione (Fervenuin (1)). **Method A.** A mixture of 5 (0.209 g, 0.001 mol) and Na₂S₂O₄ (0.522 g, 0.003 mol) in H₂O (3 mL) was stirred at room temperature for 1 h. The resulting clear solution was extracted with CHCl₃ (three 5-mL portions). The CHCl₃ extracts were dried over Na₂SO₄ and evaporated in vacuo. The residue was recrystallized from C₆H₆ to give 1 (0.17 g, 90%); mp 177–178 °C (lit.⁵ mp 178–179 °C); IR 1725, 1670 cm⁻¹ (CO); NMR (CDCl₃) δ 3.60 (s, 3 H, NCH₃), 3.93 (s, 3 H, NCH₃), 9.47 (s, 1 H, C³H); UV λ_{\max} (EtOH) 237 nm (log ϵ 3.97), 275 sh (2.99), 343 (3.16); MS *m/e* 193 (M⁺).

Anal. Calcd for C₇H₇N₅O₂: C, 43.52; H, 3.65; N, 36.26. Found: C, 43.33; H, 3.61; N, 36.19.

Method B. A mixture of 5 (0.104 g, 0.0005 mol) in dry DMF (3 mL) was refluxed for 8 h and the reaction mixture was concentrated in vacuo. The residue was recrystallized from C₆H₆ to give 1 (0.06 g, 60%), mp 177–178 °C, identical with a sample of 1 prepared by method A. Treatment of 5 (0.104 g, 0.0005 mol) with Ac₂O (3 mL) under the same conditions afforded 1 (0.02 g, 21%).

Method C. A solution of 5 (0.209 g, 0.001 mol) in EtOH (400 mL) was irradiated with a 100-W high-pressure mercury lamp surrounded by a water-cooled Pyrex filter at room temperature for 20 min. The reaction mixture was evaporated in vacuo and the residue was recrystallized from C₆H₆ to afford 1 (0.104 g, 54%), mp 177–178 °C, identical with the material prepared by methods A and B.

3-Alkyl-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-diones (3-Alkylfervenuins (12 and 13)). **General Procedure.** A mixture of 10 or 11 (0.001 mol) and Na₂S₂O₄ (0.522 g, 0.003 mol) in H₂O (3 mL) was treated as described in method A of 1.

Compound 12: recrystallized from *n*-hexane (0.176 g, 85%), mp 112–113 °C (lit.⁸ mp 127 °C); IR 1725, 1670 cm⁻¹ (CO); MS *m/e* 207 (M⁺). Anal. Calcd for C₈H₉N₅O₂: C, 46.37; H, 4.38; N, 33.80. Found: C, 46.69; H, 4.46; N, 34.15.

Compound 13: recrystallized from *n*-hexane (0.12 g, 55%), mp 88–89 °C; IR 1730, 1685 cm⁻¹ (CO); MS *m/e* 221 (M⁺). Anal. Calcd for C₉H₁₁N₅O₂: C, 48.86; H, 5.01; N, 31.66. Found: C, 48.55; H, 4.93; N, 31.64.

3-Chloro-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione (14). A mixture of 5 (0.209 g, 0.001 mol) and POCl₃ (0.6 mL) in dry DMF (3 mL) was stirred at 50 °C for 2 h. The reaction mixture was evaporated in vacuo and the residue was covered with ice-water. The precipitates were filtered and recrystallized from EtOH to yield 14 (0.19 g, 84%), mp 147 °C (lit.¹⁵ mp 146–147 °C); IR 1740, 1675 cm⁻¹ (CO); MS *m/e* 227 (M⁺), 229 (M⁺ + 2).

Anal. Calcd for C₇H₆ClN₅O₂: C, 36.93; H, 2.66; N, 30.77. Found: C, 37.06; H, 2.72; N, 30.98.

6,8-Dimethyl-3-hydroxypyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione (Fervenuinone (15)). **Method A.** A mixture of 14 (0.227 g, 0.001 mol) and HCOOH (5 mL) was refluxed for 1 h. The reaction mixture was evaporated in vacuo, and the residue was filtered by the addition of EtOH. The mass was recrystallized from EtOH and the crystals were dried (P₂O₅) in vacuo for 2 h at 120 °C to give the

anhydrous **15** (0.186 g, 89%), mp 256–258 °C (lit.¹⁵ mp 260–261 °C); IR 1710, 1660 cm⁻¹ (CO); MS *m/e* 209 (M⁺).

Anal. Calcd for C₇H₇N₅O₃: C, 40.19; H, 3.37; N, 33.48. Found: C, 39.89; H, 3.78; N, 33.40.

Method B. A mixture of **14** (0.227 g, 0.001 mol) and 2 N HCl (3 mL) at 90 °C for 30 min. The resulting solution was neutralized with 4% NaOH and allowed to stand overnight at room temperature. The precipitates were filtered and recrystallized from EtOH. The crystals were dried under the conditions described above to yield **15** (0.107 g, 51%), mp 256–258 °C, identical with a sample prepared by method A.

Method C. A solution of 3-benzyloxy-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione **16** (1.196 g, 0.004 mol) in EtOH (100 mL) containing 10% Pd-C (1 g) was hydrogenated at room temperature and at atmospheric pressure. Hydrogenation was stopped when the theoretical volume (90 mL) of H₂ gas was consumed. The solution was filtered and the filtrate was evaporated to dryness in vacuo. The residue was treated as described in method A to give **15** (0.418 g, 50%), mp 256–258 °C, identical with the material prepared by methods A and B.

3-Benzyloxy-6,8-dimethylpyrimido[5,4-*e*]-*as*-triazine-5,7(6*H*,8*H*)-dione (16). A suspension of **14** (2.27 g, 0.01 mol) in absolute benzyl alcohol (10 mL) dissolving metallic Na (0.24 g, 0.01 g-atom) was stirred at room temperature for 3 h. The precipitates were filtered, washed with H₂O, and recrystallized from EtOH to give **16** (2.24 g, 75%), mp 185–187 °C; IR 1735, 1675 cm⁻¹ (CO); MS *m/e* 299 (M⁺).

Anal. Calcd for C₁₄H₁₃N₅O₃: C, 56.18; H, 4.38; N, 23.40. Found: C, 55.82; H, 4.51; N, 23.07.

2,6,8-Trimethylpyrimido[5,4-*e*]-*as*-triazine-3,5,7(2*H*,6*H*,8*H*)-trione (2-Methylfervenulone, MSD-92 (2)). A mixture of **15** (0.209 g, 0.001 mol), methyl iodide (0.28 g, 0.002 mol), and K₂CO₃ (0.07 g, 0.0005 mol) in dry DMF (10 mL) was stirred at 50 °C for 3 h. The solution was evaporated in vacuo and the residue was covered with EtOAc (3 mL). The insoluble solid was filtered off and the filtrate was again evaporated in vacuo. The residue was recrystallized from EtOH and the separated solid was dried at 120 °C in vacuo (P₂O₅) for 2 h to give the anhydrous **2** (0.212 g, 95%) as yellow crystals: mp 180–181 °C (lit.¹⁵ mp 181–182 °C, lit.¹⁸ mp 183–183.5 °C); IR 1730, 1665 cm⁻¹ (CO); NMR (CDCl₃) δ 3.52 (s, 3 H, NCH₃), 3.54 (s, 3 H, NCH₃), 3.93 (s, 3 H, NCH₃); UV λ_{max} (H₂O) 240 nm (log ε 4.27), 280 (3.30), 415 (3.45); λ_{max} (MeOH) 218 nm (log ε 4.10), 285 (3.86), 415 (2.95); MS *m/e* 223 (M⁺).

Anal. Calcd for C₈H₉N₅O₃: C, 43.05; H, 4.06; N, 31.38. Found: C, 43.12; H, 4.29; N, 31.72.

5-Acetylamino-1,3-dimethylbarbituric Acid (17). Method A. A solution of **5** (0.209 g, 0.001 mol) in a mixture of Ac₂O (2 mL) and AcOH (2 mL) was refluxed for 1 h. The reaction mixture was evaporated in vacuo and the residue was recrystallized from EtOH to give **17** (0.107 g, 50%), mp 230–231 °C; MS *m/e* 213 (M⁺).

Anal. Calcd for C₈H₁₁N₃O₄: C, 45.07; H, 5.20; N, 19.71. Found: C, 44.89; H, 5.08; N, 19.76.

Method B. A solution of 5-amino-1,3-dimethylbarbituric acid **18**²⁰ (0.171 g, 0.001 mol) and a mixture of Ac₂O (2 mL) and AcOH (2 mL) was refluxed for 1 h and the reaction mixture was treated as described above to give **17** (0.1 g, 47%), mp 230–231 °C, identical with a material prepared by method A.

5,7-Dimethylimidazo[4,5-*e*]-*as*-triazine-6(7*H*)-one (19). A mixture of **5** (0.209 g, 0.001 mol) and 0.5% NaOH (10 mL) was heated at 90 °C for 1 h. The resulting solution was acidified (pH 4) by the addition of AcOH and the precipitated solid was filtered. Recrystallization from EtOH gave **19** (0.066 g, 40%), mp 146–147 °C; IR 1750 cm⁻¹ (CO); NMR (Me₂SO-*d*₆) δ 3.31 (s, 3 H, NCH₃), 3.40 (s, 3 H, NCH₃), 10.23 (s, 1 H, C³H); MS *m/e* 165 (M⁺).

Anal. Calcd for C₆H₇N₅O: C, 43.63; H, 4.27; N, 42.41. Found: C, 43.55; H, 4.31; N, 42.05.

Acknowledgment. The authors are grateful to Professor Fumio Yoneda of Kumamoto University for helpful discussions. The authors also thank Mr. Katsuhiko Nagahara of Kitasato University for his cooperation in spectral measurements.

Registry No.—1, 483-57-8; 2, 22712-32-9; 4, 40012-15-5; 5, 62758-20-7; 10, 60026-36-0; 11, 63069-55-6; 12, 25696-97-3; 13, 64235-46-7; 14, 18969-84-1; 15, 18969-83-0; 16, 64235-47-8; 17, 64235-48-9; 18, 54632-31-4; 19, 64216-10-0; benzyl alcohol, 100-51-6.

References and Notes

- (1) Preliminary reports: (a) M. Ichiba, K. Senga, S. Nishigaki, and F. Yoneda, *J. Heterocycl. Chem.*, **14**, 175 (1977); (b) K. Senga, M. Ichiba, and S. Nishigaki, *Heterocycles*, **6**, 273 (1977).
- (2) Recent advances in the chemistry and biology of pyrimido[5,4-*e*]-*as*-triazines have been reviewed by D. J. Brown and R. K. Lynn, "Chemistry and Biology of Pteridines", W. Pfeleiderer, Ed., Walter de Gruyter, New York, N.Y., 1975, pp 575–601.
- (3) K. Senga, H. Kanazawa, and S. Nishigaki, *J. Chem. Soc., Chem. Commun.*, 155 (1976).
- (4) K. Senga, H. Kanazawa, and S. Nishigaki, *J. Chem. Soc., Chem. Commun.*, 588 (1976).
- (5) W. Pfeleiderer and K.-H. Schündehütte, *Justus Liebigs Ann. Chem.*, **615**, 42 (1958).
- (6) H. Bredereck, F. Effenberger, and G. Simchen, *Chem. Ber.*, **96**, 1350 (1963).
- (7) F. Yoneda, T. Nagamatsu, and K. Shinomura, *J. Chem. Soc., Perkin Trans. 1*, 713, (1976).
- (8) G. Blankenhorn and W. Pfeleiderer, *Chem. Ber.*, **105**, 3334 (1972).
- (9) In a preliminary communication,^{1a} it was speculated that the reaction proceeds via the nucleophilic attack of the oxime group of **4** on the Vilsmeier reagent; however, the initial formation of intermediate **6** seems to be favorable since the nucleophilicity of the hydrazino group is greater than that of the oxime group.
- (10) G. Nübel and W. Pfeleiderer, *Chem. Ber.*, **98**, 1060 (1965).
- (11) For example, see E. C. Taylor, "Topics in Heterocyclic Chemistry", R. N. Castle, Ed., Wiley, New York, N.Y., 1969, pp 1–34.
- (12) G. D. Daves, R. K. Robins, and C. C. Cheng, *J. Am. Chem. Soc.*, **84**, 1724 (1962).
- (13) K. Tanabe, Y. Asahi, M. Nishikawa, T. Shima, Y. Kuwada, T. Kanazawa, and K. Ogata, *Takeda Kenkyusho Nempo*, **22**, 133 (1963); *Chem. Abstr.*, **60**, 13232d (1964).
- (14) C. Temple, C. L. Kussner, and J. A. Montgomery, *J. Org. Chem.*, **34**, 2102 (1969).
- (15) E. C. Taylor and F. Sowinski, *J. Org. Chem.*, **40**, 2321 (1975).
- (16) F. Yoneda and T. Nagamatsu, *Bull. Chem. Soc. Jpn.*, **48**, 2884 (1975).
- (17) Hydrolysis of an active chloro compound with formic acid has been reported: C. Temple, B. H. Smith, and J. A. Montgomery, *J. Org. Chem.*, **23**, 3601 (1972).
- (18) T. W. Miller, L. Chalet, B. Arison, R. W. Walker, N. R. Trenner, and F. J. Wolf, "Antimicrobial Agents and Chemotherapy", J. C. Sylvester, Ed., Medical Textbook Publishers, New York, N.Y., 1963, p 58.
- (19) (a) E. Ochiai, "Aromatic Amine Oxides", Elsevier, New York, N.Y., 1967, pp 247–339; (b) A. R. Katritzky and J. M. Lagowski, "Chemistry of Heterocyclic N-Oxides", Academic Press, New York, N.Y., 1971, pp 258–319.
- (20) H. Biltz and P. Damm, *Chem. Ber.*, **46**, 3662 (1913).
- (21) It is interesting to note that no reaction occurred when **5** was refluxed in acetic acid alone for 1 h, and **5** being recovered.
- (22) During the course of this study, Yoneda et al. reported the ring contraction of pyrimido[5,4-*e*]-*as*-triazines and their 4-oxides to imidazo[4,5-*e*]-*as*-triazines: F. Yoneda, T. Nagamatsu, and M. Kawamura, *J. Chem. Soc., Chem. Commun.*, 658 (1976); F. Yoneda, M. Kawamura, T. Nagamatsu, K. Kurehara, A. Hoshi, and M. Iigo, *Heterocycles*, **4**, 1503 (1976).
- (23) The carbonyl bands of imidazo[4,5-*e*]-*as*-triazines prepared by Yoneda et al. have been observed at 1760 cm⁻¹ (see ref 22).
- (24) E. C. Taylor, Y. Maki, and A. McKillop, *J. Org. Chem.*, **37**, 1601 (1972).